# A Study of HS-20094 in T2DM Participants

> **NCT06118008** · PHASE2 · COMPLETED · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HS-20094 5mg
- **DRUG:** HS-20094 10mg
- **DRUG:** HS-20094 15mg
- **DRUG:** HS-20094 20mg

## Key facts

- **NCT ID:** NCT06118008
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-31
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-01-04
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118008, "A Study of HS-20094 in T2DM Participants". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06118008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*